Business Description
Cullinan Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US2300311063
Share Class Description:
CGEM: Ordinary SharesTotal Employee Number:
109Description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 161.54 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13 | |||||
3-Year EPS without NRI Growth Rate | -20.8 | |||||
3-Year FCF Growth Rate | -2.8 | |||||
3-Year Book Growth Rate | -16.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.24 | |||||
9-Day RSI | 79.49 | |||||
14-Day RSI | 72.27 | |||||
3-1 Month Momentum % | 18.96 | |||||
6-1 Month Momentum % | 42.2 | |||||
12-1 Month Momentum % | 122.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.42 | |||||
Quick Ratio | 8.42 | |||||
Cash Ratio | 8.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.6 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -50.16 | |||||
ROA % | -46.11 | |||||
ROIC % | -200.27 | |||||
3-Year ROIIC % | 684.63 | |||||
ROC (Joel Greenblatt) % | -9552.33 | |||||
ROCE % | -54.22 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.17 | |||||
Price-to-Tangible-Book | 4.17 | |||||
EV-to-EBIT | -4.55 | |||||
EV-to-EBITDA | -4.55 | |||||
EV-to-Forward-Revenue | 18.54 | |||||
EV-to-FCF | -6.33 | |||||
| Price-to-Net-Current-Asset-Value | 4.47 | |||||
| Price-to-Net-Cash | 4.58 | |||||
Earnings Yield (Greenblatt) % | -21.98 | |||||
FCF Yield % | -11.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGEM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cullinan Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.1 | ||
| Beta | -0.2326 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 0.95 | ||
| Volatility % | 73.43 | ||
| 14-Day RSI | 72.27 | ||
| 14-Day ATR ($) | 1.164397 | ||
| 20-Day SMA ($) | 18.209 | ||
| 12-1 Month Momentum % | 122.52 | ||
| 52-Week Range ($) | 5.68 - 21.22 | ||
| Shares Outstanding (Mil) | 64.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cullinan Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cullinan Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 79 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 17.61 (-0.23%) | ||
| General meeting for 2026 | 2026-06-16 10:00 | 13.61 (-2.37%) | ||
| Guidance call for 2026 | 2026-06-10 08:30 | 13.18 (-1.42%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 14.99 (+1.08%) | ||
| Guidance call for 2026 | 2026-03-10 16:20 | 15.31 (+0.07%) | ||
| Annual report for 2025 | 2026-03-10 | 15.31 (+0.07%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 15.31 (+0.07%) | ||
| TD Cowen 46th Annual Healthcare Conference | 2026-03-03 13:10 | 15.99 (+5.06%) | ||
| Guidance call for 2026 | 2026-02-19 10:00 | 12.44 (+1.97%) |
Show
Entries
Cullinan Therapeutics Inc Frequently Asked Questions
What is Cullinan Therapeutics Inc(CGEM)'s stock price today?
The current price of CGEM is $20.85. The 52 week high of CGEM is $21.22 and 52 week low is $5.68.
When is next earnings date of Cullinan Therapeutics Inc(CGEM)?
The next earnings date of Cullinan Therapeutics Inc(CGEM) is 2026-11-06 Est..
Does Cullinan Therapeutics Inc(CGEM) pay dividends? If so, how much?
Cullinan Therapeutics Inc(CGEM) does not pay dividend.
Guru Commentaries on NAS:CGEM
No articles.
Press Release
Articles on Cullinan Therapeutics Inc
Cullinan Therapeutics (CGEM) Advances in Phase 3 Trial, Shares Near 2-Year High Amid Mixed Signals
1 day ago
Headlines
See More- 1
Aug 13, 2026
Cullinan rises as lung cancer drug succeeds in late-stage trial
Seeking Alpha • 5:52am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers